Antimicrobial Resistance: Challenges and Solutions in Antibiotic Therapy

Dear Colleagues,

Antimicrobial resistance (AMR) became one of the main concerns in public health worldwide due to its prevalence. Microorganisms’ adaptation to the activity of antibiotics is a dynamic phenomenon resulting in the lack of therapeutical efficacy and poses a challenge in developing more efficient therapeutical strategies. Moreover, the apparition of multidrug resistant (MDR) bacteria, extensively drug-resistant (XDR) bacteria and superbugs lead to a decrease or even loss of antibiotics efficacy and an increase in morbidity and mortality resulting in reducing the rate of success of conventional antibiotherapy. Also, the recent COVID-19 pandemic forced the use of complex therapeutical strategies with antibiotics to manage bacterial overgrowth coinfections/PDR (pandrug-resistant), a fact already confirmed by other respiratory infections like H1N1, SARS and MERS.

A World Health Organization report from 2021 warned that AMR became very serious and by 2050 might lead to up to 10 million deaths yearly, from different causes like the misuse of antibiotics in human therapy or the abuse of antibiotics for improving some species of plants and animals.

The need for new approach strategies of AMR became stringent and aims to offer improved pharmacotherapies by means of developing antibiotics with new action mechanisms and/or innovative drug delivery systems with already approved molecules.

This special issue intends to present new strategies for antibiotherapy of difficult to treat infections starting from the pharmacology of new compounds (with new mechanisms) to delivery systems and other drug modifications for molecules already available on the market.

For this special issue authors are invited to submit their original or review articles on the following research directions (but not limited to):

• New targets for antibiotherapy;
• Discovery and development of new therapeutical strategies;
• Treatment of complications related to lack of efficacy of antibiotherapy;
• MDR, XDR, PDR – microorganisms adapting to antibiotherapy;
• New drug delivery systems for antibiotics;
• Design of new pharmaceutical dosage forms.

Dr. Anca-Maria Arseniu
Dr. Adriana Aurelia Chiș
Dr. Claudiu Morgovan
Dr. Luca-Liviu Rus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• antimicrobial resistance
• drug discovery
• drug delivery systems
• pharmaceutical formulation design